15 results about "Ichthyosis" patented technology

The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1 / 2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

The invention discloses a skin cell nucleus nutritional agent containing traditional Chinese medicine components and capable of improving ichthyosis and a preparation method, and relates to the technical field of preparation of skin cell nucleus nutritional agents. Comprising the following raw materials: modified vitamin A propionate, a traditional Chinese medicine extract, modified hydrogenated lecithin, squalane, beewax, stearyl alcohol, vaseline, glycerin, sodium hyaluronate, beta-glucan, propylene glycol, potassium cetyl phosphate, a preservative, allantoin, deionized water, triethanolamine and a lipid solvent. According to the invention, the modified tretinoin propionate is added, and the modified tretinoin propionate is subjected to double-grafting modification through glycyrrhetinic acid-hyaluronic acid oligosaccharide and is gently combined with a basal cell tretinoin receptor in a targeted manner, so that excessive proliferation of basal cells can be inhibited, and normal differentiation of keratinocytes can be promoted; wherein the glycyrrhetinic acid component can resist inflammation, relieve and reduce self-irritation, and the hyaluronic acid oligosaccharide can improve targeting and transdermal efficiency, avoid light / oxygen degradation and provide a core regulation effect for restoring the 28-day metabolic cycle of basal cells.

The present disclosure relates to topical treatment of skin diseases, such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization, using (a) a JAK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.

A fire-retardant topical formulation comprising glycerol and urea in a ratio of 1:1 to 1:30 is provided. The formulation may further comprise polyvinyl pyrrolidone and / or ethylhexylglycerin, and / or a barrier forming agent and / or a stabilising agent. The formulation may be a moisturiser, shampoo, conditioner, hair dye, sun cream, aftersun composition, emollient or medical composition. The formulation may be for use in treating a skin condition, such as eczema, dermatitis, psoriasis, elderly dry and itchy skin, ichthyosis, rash, or infection. The composition when transferred to a fabric suppresses the flammability of the fabric and is also capable of being removed from the fabric by washing. A preferred formulation comprises 1% phenoxyethanol, 10% urea, 10% sodium lactate (60% solution), 1% lactic acid, 1% glycerol, 3% ethylhexylglycerin, 2% polyacrylate crosspolymer-6, 0.5% polyvinylpyrrolidone and 71.5% water by weight. A fire-retardant topical formulation comprising 1% glycerol, 2% polyacrylate crosspolymer-6, 10% sodium lactate solution, 1% phenoxyethanol, 1% lactic acid, 3% ethylhexylglycerin and 0.5% polyvinylpyrrolidone by weight is also disclosed. [Fig: None]

The present disclosure relates to topical treatment of skin diseases, such as psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization, using (a) a JAK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) vitamin D3, a vitamin D3 analog, or a pharmaceutically acceptable salt thereof.

A topical application composition comprising a TRPV3 inhibitor, such as KM-001, significantly reduces the severity of dermatological lesions, pruritus, and combinations thereof in patients suffering from dermatological disorders, such as keratosis, chronic simple moss, and ichthyosis.

The invention discloses a construction method and application of a gene knockout mouse model based on ichthyosis virulence gene GLTP. The NCBI (National Center of Biotechnology Information) gene ID (Identity) of the GLTP gene is 51228. The Gltp gene knockout mouse model is constructed by the following method: assembling sgRNA of a targeted mouse Gltp gene and Cas9 protein in vitro to obtain a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9-sgRNA compound; performing micro-injection on the compound to fertilized eggs of mice, and transplanting the fertilized eggs to obtain positive F0-generation mice; after the positive F0-generation mice and wild mice are mated, heterozygotes are screened, the heterozygotes are subjected to selfing, and the F0-generation mice are obtained. The GLTP gene is clearly identified as a new pathogenic gene of ichthyosis for the first time, the constructed Gltp gene knockout mouse model can spontaneously generate ichthyosis-like skin lesion, human disease characteristics are simulated, and a more ideal tool is provided for researching ichthyosis disease pathogenesis and screening targeted drugs.

The invention relates to methods of treating ichthyosis in a subject with an inhibitor of the interleukin 36 (IL-36) pathway, and methods of selecting a subject for therapy with the IL-36 pathway inhibitor.

The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1 / 2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

The present invention provides, among other things, methods of treating pruritic or inflammatory skin diseases or disorders, or pruritus associated with a disease or disorder, with an anti-OSMRβ antibody, including methods of treating pruritus, associated with atopic dermatitis, chronic kidney disease-associated pruritus, uremic pruritus or prurigo nodularis, chronic idiopathic pruritus, chronic idiopathic urticaria, chronic spontaneous urticaria, cutaneous amyloidosis, lichen simplex chronicus, plaque psoriasis, lichens planus, inflammatory ichthyosis, mastocytosis and bullous pemphigoid, comprising a step of administering to a subject in need of treatment an anti-OSMRβ antibody at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of the disease or disorder relative to a control.

The present invention provides a compound of formula (I) for use in the treatment or prevention of pathological conditions associated with increased expression and activity of TREX2, wherein: A1 is a group of formula (II); a2 is a ring system consisting of one or two rings wherein each ring is saturated, partially saturated or unsaturated and has 5 or 6 members selected from the group consisting of: N, O, S, C, NRp, CRz and C (Rz) 2; a3 represents X7-(X8) n; x1 represents CR1 or N; x2 represents CR2 or N; x3 represents CR3 or N; x4 represents CR4 or N; x5 represents CR5 or N; x6 represents CR6 or N; x7 represents CR7 or N; and X8 represents CR8 or N; with the proviso that one, two or three of X1 to X8 are N; and n is an integer selected from 0 or 1. The present invention also provides compounds of formula (Ibis), pharmaceutical compositions comprising the same, and methods of making the same.

The invention provides a traditional Chinese medicine preparation for treating ichthyosis and a preparation method of the traditional Chinese medicine preparation. The traditional Chinese medicine preparation is prepared from the following raw materials by weight according to the principle of monarch, minister, assistant and guide: 10-35g of salvia miltiorrhiza, 10-15g of rhizoma smilacis glabrae, 10-40g of radix sophorae flavescentis, 10-40g of cortex dictamni, 10-40g of radix paeoniae rubra, 10-30g of rehmannia, 10-15g of radix pseudostellariae, 10-40g of bighead atractylodes rhizome, 10-15g of glossy privet fruit, 20-60g of motherwort, 10-15g of radix clematidis and 10-40g of honeysuckle stem. The traditional Chinese medicine has the effects of softening hardness to dissipate stagnation, dispelling wind, moistening dryness, relieving itching, promoting blood circulation to remove blood stasis, dredging collaterals, tonifying kidney, nourishing blood, tonifying qi and blood, nourishing blood, moistening skin, nourishing yin, promoting salivation and the like, and is specially used for treating ichthyosis. The medicine is prepared into powder, external use is facilitated, the treatment operation method is simple, and the medicine is suitable for industrial production and application.

The application discloses a kit for constructing ABCA12 gene mutation speckled ichthyosis model pig nuclear transfer donor cells and application thereof. The application provides a kit comprising ABCA12-gRNA1 shown in SEQ ID NO: 16, ABCA12-gRNA4 shown in SEQ ID NO: 17 and NCN protein. The application also provides a method for preparing a recombinant pig cell: ABCA12-gRNA1, ABCA12-gRNA4 and NCN protein are co-transfected into a pig cell to obtain a recombinant pig cell. The recombinant pig cell is a recombinant pig cell with ABCA12 gene mutation. The kit is used for: preparing a recombinant pig cell; preparing a speckled ichthyosis model pig; preparing a speckled ichthyosis cell model or a speckled ichthyosis tissue model or a speckled ichthyosis organ model. The application has great application value for research and development of speckled ichthyosis drugs and revealing the pathogenesis of the disease.

The present invention provides, inter alia, methods of treating a pruritic or inflammatory skin disease or disorder, or pruritus associated with a certain disease or disorder, using anti-OSMR [beta] antibodies, comprising methods of treating pruritus associated with atopic dermatitis, chronic kidney disease-associated pruritus, uremic pruritus or prurigo nodularis, chronic idiopathic pruritus, chronic idiopathic urticaria, chronic spontaneous urticaria, skin amyloidosis, chronic simple moss, psoriasis plaque, moss planus, inflammatory lepidosis, and the like. The present invention relates to methods for treating mastocytoplasia and bullous pemphigus, comprising the step of administering an anti-OSMR [beta] antibody to a subject in need of treatment at a therapeutically effective dose and administration interval relative to a control for a treatment cycle sufficient to ameliorate, stabilize, or alleviate one or more symptoms of the disease or condition.

The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1 / 2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.